CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
REVENUES:
Total revenues	$ 372,845	$ 317,448	$ 746,292	$ 621,193
OPERATING EXPENSES:
Cost of sales	79,019	56,305	161,352	106,311
Research and development	175,582	143,039	359,530	288,042
Selling, general and administrative	153,280	143,505	291,616	263,524
Intangible asset amortization and contingent consideration	10,227	13,411	23,429	22,336
Gain on sale of intangible assets	20,000	0	20,000	0
Total operating expenses	398,108	356,260	815,927	680,213
LOSS FROM OPERATIONS	(25,263)	(38,812)	(69,635)	(59,020)
Equity in the loss of BioMarin/Genzyme LLC	(107)	(220)	(39)	(743)
Interest income	5,569	2,983	10,803	6,055
Interest expense	(12,225)	(10,040)	(23,787)	(20,159)
Other income, net	2,849	543	2,677	4,015
LOSS BEFORE INCOME TAXES	(29,177)	(45,546)	(79,981)	(69,852)
Benefit from income taxes	(12,385)	(8,713)	(19,040)	(16,729)
NET LOSS	$ (16,792)	$ (36,833)	$ (60,941)	$ (53,123)
NET LOSS PER SHARE, BASIC AND DILUTED	$ (0.09)	$ (0.21)	$ (0.35)	$ (0.31)
Weighted average common shares outstanding, basic and diluted	176,873	174,374	176,405	173,547
COMPREHENSIVE INCOME (LOSS)	$ 10,624	$ (56,511)	$ (38,523)	$ (80,597)
Net Product Revenues
REVENUES:
Total revenues	367,786	315,926	736,885	618,116
Royalty and Other Revenues
REVENUES:
Total revenues	$ 5,059	$ 1,522	$ 9,407	$ 3,077